Latest News-Ascletis Pharma Inc. Mediaroom_Page

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

- Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis...

2025-10-14 18:00 2015

Ascletis Selects a Best-In-Class Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for Clinical Development

- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC35 was approxim...

2025-10-13 08:10 2036

Ascletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide Monotherapy

- The gastrointestinal (GI) tolerability of ASC47 in combination with semaglutide was sign...

2025-09-22 08:10 2327

Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025

--Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis...

2025-09-18 07:30 2196

Ascletis Presented Results from Cohorts 1 and 2 of 28-day Multiple Ascending Dose Study of Its Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting

- ASC30 once-daily oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight r...

2025-09-17 07:30 2113

Ascletis to Present 28-day Multiple Ascending Dose Study Results of Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting

- Ascletis to present data from the U.S. Phase Ib clinical study of ASC30 oral tablet in oral disc...

2025-09-02 18:00 1755

Ascletis Announces Favorable and Differentiated Pharmacokinetic Profile of ASC30 Oral Once-Daily Tablet in Its U.S. Phase Ib Multiple Ascending Dose Study

- ASC30 oral once-daily tablet demonstrated approximately 2.3-fold to 3.3-fold greater dru...

2025-08-28 07:45 1651

Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an Animal Model of Obesity

- Combination of a low dose of ASC47 with ASC31, a novel peptide agonist targeting bothGLP-1 recep...

2025-08-18 08:15 2108

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model

- The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resul...

2025-08-13 07:00 2162

Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Small Molecule Oral GLP-1R Agonist, ASC30, in Participants with Obesity or Overweight

- 13-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of two ...

2025-08-05 18:50 1911

Ascletis Announces First Participants with Obesity or Overweight Dosed in Its U.S. 12-week Phase IIa Study Evaluating Once-Monthly Subcutaneous Depot Formulation of Small Molecule GLP-1R Agonist ASC30

- First participants with obesity or overweight with at least one w eight-related comorbidi...

2025-07-28 08:15 2510

Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity

- The combination study, conducted in the U.S., is designed to evaluate the safety, tolera...

2025-07-15 07:00 2380

Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30

- First participants with obesity or overweight with at least one weight-r elatedcomorbidity have b...

2025-07-03 07:00 2493

Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)

HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces tha...

2025-06-09 08:15 2353

Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity

- The combination study is designed to evaluate the safety and preliminary efficacy of a single-dos...

2025-05-20 18:00 2925

Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity

HONG KONG, May 6, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces oral ...

2025-05-06 16:55 3243

Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA

- ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from...

2025-04-23 07:30 3279

Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist

-Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 3...

2025-03-31 19:00 2990

Ascletis Pharma to Host Obesity Portfolio Webinar on April 2, 2025

HONG KONG, March 20, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces it...

2025-03-20 19:00 4254

Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide

* ASC47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of ob...

2025-03-12 07:30 3179